Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.63B P/E 386.46 EPS this Y -616.70% Ern Qtrly Grth -
Income 40.72M Forward P/E -29.21 EPS next Y 11.80% 50D Avg Chg 11.00%
Sales 216.67M PEG 2.03 EPS past 5Y - 200D Avg Chg 74.00%
Dividend N/A Price/Book 5.91 EPS next 5Y -4.30% 52W High Chg -15.00%
Recommedations 2.10 Quick Ratio 4.13 Shares Outstanding 63.15M 52W Low Chg 217.00%
Insider Own 2.42% ROA -14.87% Shares Float 61.63M Beta 1.57
Inst Own 91.56% ROE 8.17% Shares Shorted/Prior 6.24M/5.41M Price 50.24
Gross Margin 64.94% Profit Margin 18.79% Avg. Volume 1,521,429 Target Price 37.70
Oper. Margin -39.96% Earnings Date May 1 Volume 1,546,761 Change -3.99%
About Schrodinger, Inc.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schrodinger, Inc. News
04/18/24 Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/11/24 Institutional investors must be pleased after a 11% gain last week that adds to Schrödinger, Inc.'s (NASDAQ:SDGR) one-year returns
04/10/24 Schrödinger to Announce First Quarter 2024 Financial Results on May 1
04/02/24 5 Healthcare Stocks to Buy for 2024
03/24/24 13 Best Stocks to Buy and Hold According to Bill Gates’ Portfolio
03/20/24 Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting
03/18/24 Billionaire Bill Gates Has 35% of His Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks: Are They No-Brainer Buys?
03/01/24 The Hot List: 3 AI Stocks Worth Buying on Weakness
03/01/24 Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Slashed This Year's Estimates
02/29/24 Q4 2023 Schrodinger Inc Earnings Call
02/29/24 Schrödinger, Inc. (NASDAQ:SDGR) Q4 2023 Earnings Call Transcript
02/28/24 Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
02/28/24 Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
02/28/24 Schrodinger Inc (SDGR) Reports Strong Revenue Growth in Q4 and Full-Year 2023
02/28/24 Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
02/26/24 Countdown to Schrodinger, Inc. (SDGR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
02/20/24 Schrödinger to Participate in Upcoming Investor Conferences
02/19/24 Double Your Money: 3 Growth Stocks to Grab in 2024
02/17/24 Schrödinger, Inc.'s (NASDAQ:SDGR) Intrinsic Value Is Potentially 86% Above Its Share Price
02/14/24 Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28
SDGR Chatroom

User Image scott52 Posted - 4 days ago

$SDGR I have no idea why this didn't break down to $20. It's a complete mystery.

User Image Stock_Titan Posted - 4 days ago

$SDGR Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/SDGR/schrodinger-reports-inducement-grants-under-nasdaq-listing-rule-5635-qec2gjqyusgk.html

User Image scott52 Posted - 6 days ago

$SDGR Should finally break down tomorrow.

User Image SacramentoKings Posted - 6 days ago

@Didgeman I’ll stay on the sidelines for now. Have you looked into Shrodinger $SDGR or Exscientia $EXAI ?? Both look promising platforms.

User Image ScamBuster0 Posted - 1 week ago

@MariaMetro Interesting, but we've been doing that with an AI system for years because not all pharma targets are proteins, most are not. One doesn't need a quantum computer unless looking for protein binding as a more complex 3D receptor target area for a ligand. About 10 years ago we used a 3D X-Ray diffraction model of a protein target area with $SDGR and old digital computers to design small molecule binders. And it worked. However, the stuff about changing the time for preclinical assessment or the percentages of clinical failures will not change due to quantum ligand structure design. Those percentages are a function of the predictive quality of the assay systems. Nor will it get to clinical trials faster because the FDA focuses on safety, while efficacy is a risk for the sponsor.

User Image BigLineSwings Posted - 1 week ago

$SDGR some gaps to the upside here **

User Image Stock_Titan Posted - 1 week ago

$SDGR Schrödinger to Announce First Quarter 2024 Financial Results on May 1 https://www.stocktitan.net/news/SDGR/schrodinger-to-announce-first-quarter-2024-financial-results-on-may-9q1d7zvthfk8.html

User Image ApexSeidon Posted - 1 week ago

$SDGR 30C STO 6/21exp $718k 2.4 Avg

User Image Pyeha Posted - 1 week ago

$SDGR lol

User Image Tawiskaron Posted - 1 week ago

Great day for $SDGR, very impressed how $DJT is resisting !

User Image shavitmi Posted - 2 weeks ago

$SDGR from lates cc "We reported that we continue to have four customers with annual contract value of at least $5 million, and the average contract value for customers over $5 million grew significantly to $6.7 million. The number of customers with ACV of at least $1 million has increased from 18 to 27, as more and more emerging companies recognize the value of increasing their scale of adoption. "

User Image maizeblue22 Posted - 2 weeks ago

$SDGR I’m bullish here. Their small molecule and biologics dev packages are strong and easy to use. What will it take to drive up SP from this level? Greater adoption by big pharma?

User Image Tawiskaron Posted - 2 weeks ago

$SDGR future's bright!

User Image shavitmi Posted - 2 weeks ago

$SDGR i think Takeda acquired Nimbus thanks to SDGR . AI in drug reaserch can be a game changer. Im in

User Image scott52 Posted - 2 weeks ago

$SDGR Let's see if it can hold the $23.45 level.

User Image Luka_Brasi Posted - 3 weeks ago

$SDGR AI, biotech, and 3D manufacturing, what could go wrong with that hat trick. Turns out plenty. Old school turd.

User Image Galactic_Stock_Savant Posted - 03/31/24

$RXRX Just remember $RXRX recursion pharmaceuticals remains the most advanced in the field of Artificial intelligence biotech stocks when compared across the sector It’s the only play that does real life wet tests with real medicines in a lab The rest just do simulations on the computer and have no physical backing, no brainer to have a heavy position in rxrx Chart below $RLAY $SDGR $LTRN $NVDA

User Image Galactic_Stock_Savant Posted - 03/31/24

Just remember $RXRX recursion pharmaceuticals remains the most advanced in the field of Artificial intelligence biotech stocks when compared across the sector It’s the only play that does real life wet tests with real medicines in a lab The rest just do simulations on the computer and have no physical backing, no brainer to have a heavy position in rxrx $RLAY $SDGR $LTRN $NVDA

User Image Galactic_Stock_Savant Posted - 03/30/24

$RXRX recursion remains the most advanced in the field of Artificial intelligence biotech stocks when compared across the sector $RLAY $SDGR $LTRN $NVDA

User Image TICKERTUTOR Posted - 03/27/24

$IBIO So just for context, this is how much other AI drug discovery platform cos are being valued here… $SDGR 1.85B, $RXRX 2.4B, $EXAI 725M $ABSI 600M. No suggestion here… just context.

User Image scott52 Posted - 03/25/24

$SDGR Am I the only one getting the $22 gap fill vibe? I'll jump on it when it happens.

User Image Stock_Titan Posted - 1 month ago

$SDGR Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting https://www.stocktitan.net/news/SDGR/schrodinger-highlights-discovery-of-sgr-1505-clinical-stage-malt1-4xxkumsrxvfy.html

User Image Stock_Titan Posted - 1 month ago

$SDGR Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/SDGR/schrodinger-reports-inducement-grants-under-nasdaq-listing-rule-5635-0297caay30zx.html

User Image GuerillaStockTrading Posted - 1 month ago

Software company few have heard of. Bill and Melinda Gates Foundation holds 11% of the outstanding stock. It's not just AI; it's a leap in drug development and materials science. $SDGR https://www.guerillastocktrading.com/unveiling-schrodinger-more-than-just-an-ai-stock/

User Image scott52 Posted - 1 month ago

$SDGR This is my favorite chart. We are at the beginning. SGR-1505 phase 1 started in August 2023, if I'm not mistaken, with initial data at the end of 2024 or early 2025. We saw a bump earlier in the year but that was probably more driven by rates than anything else. We may see some "hype" at the end of the year. I'm keeping a long position in my long-term account. But I'll continue to flip burgers in my trading account.

User Image BuffaloEngine Posted - 1 month ago

$SDGR great read definitely want to check this out

User Image BuffaloEngine Posted - 1 month ago

$SDGR this thing is topped out.

User Image GuerillaStockTrading Posted - 1 month ago

Schrodinger Inc. $SDGR is not just a company. It's revolutionizing drug discovery with AI. Discover how they're changing the game. https://www.guerillastocktrading.com/schrodinger-pioneering-drug-discovery-with-ai-and-physics-based-modeling/

User Image JimmyBluechips Posted - 1 month ago

The smart money will come here eventually $GNRC $SDGR

User Image pfchangs Posted - 1 month ago

$SDGR if AGI happens virtually every software company that doesn't have their fingers in the AI pie will be put out of business

Analyst Ratings
Citigroup Buy Mar 1, 24
Goldman Sachs Neutral Mar 1, 24
Keybanc Overweight Feb 29, 24
Citigroup Buy Feb 29, 24
B of A Securities Neutral Feb 29, 24
Piper Sandler Overweight Feb 29, 24
TD Cowen Outperform Jan 26, 24
Craig-Hallum Buy Jan 19, 24
Keybanc Overweight Dec 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Herman Jenny SVP & Controller SVP & Controller Sep 15 Option 1.20 4,545 5,454 12,548 09/18/23
Tran Yvonne EVP, CLO & CPO EVP, CLO & CPO May 22 Sell 37.52 22,960 861,459 12,721 05/24/23
Tran Yvonne EVP, CLO & CPO EVP, CLO & CPO May 22 Option 3.92 22,960 90,003 20,681 05/24/23
Lorton Kenneth Patrick EVP & Chief Technolo.. EVP & Chief Technology Officer May 23 Sell 40.0587 10,000 400,587 47,388 05/24/23
Thornberry Nancy Director Director May 22 Sell 35 14,850 519,750 05/23/23
Thornberry Nancy Director Director May 22 Option 11.52 14,850 171,072 14,850 05/23/23
Thornberry Nancy Director Director Aug 11 Option 11.52 4,950 57,024 4,950 08/12/22
Thornberry Nancy Director Director Aug 11 Sell 35 4,950 173,250 08/12/22
- - - Jun 25 Sell 78.28 299,027 23,407,834 6,657,197 06/25/21
- - - Jun 23 Sell 76.41 182,948 13,979,057 6,956,224 06/23/21
- - - Jun 21 Sell 74.78 165,178 12,352,011 7,139,172 06/21/21
- - - Jun 16 Sell 75.36 141,072 10,631,186 7,304,350 06/16/21
- - - May 26 Sell 67.2 74,056 4,976,563 7,445,422 05/26/21
- - - Apr 21 Sell 72.59 90,000 6,533,100 7,864,405 04/21/21
- - - Apr 15 Sell 77.07 120,400 9,279,228 7,954,405 04/15/21
- - - Apr 09 Sell 76.03 107,204 8,150,720 8,074,805 04/09/21
- - - Apr 01 Sell 75.33 184,043 13,863,959 8,182,009 04/01/21
- - - Mar 24 Sell 75.07 150,000 11,260,500 8,366,052 03/24/21
- - - Mar 11 Sell 75.27 125,665 9,458,805 8,632,225 03/11/21
Sender Gary Director Director Mar 10 Option 11.16 28,775 321,129 28,775 03/10/21
Sender Gary Director Director Mar 10 Sell 66.55 28,775 1,914,976 03/10/21
Lorton Kenneth Patrick EVP & Chief Technolo.. EVP & Chief Technology Officer Mar 10 Option 10.67 5,836 62,270 53,718 03/10/21
Friesner Richard Director Director Mar 10 Sell 67.76 64,000 4,336,640 714,925 03/10/21
Daniel Jennifer EVP & Chief HR Offic.. EVP & Chief HR Officer Mar 08 Option 17 836 14,212 7,524 03/08/21
Daniel Jennifer EVP & Chief HR Offic.. EVP & Chief HR Officer Mar 08 Sell 74.65 836 62,407 6,688 03/08/21
- - - Mar 05 Sell 80.43 100,000 8,043,000 8,757,890 03/05/21
D'Cruz Cony EVP & Chief Business.. EVP & Chief Business Officer Mar 05 Option 3.07 2,800 8,596 2,800 03/05/21
D'Cruz Cony EVP & Chief Business.. EVP & Chief Business Officer Mar 05 Sell 106.9 4,800 513,120 151,082 03/05/21
Daniel Jennifer EVP & Chief HR Offic.. EVP & Chief HR Officer Mar 02 Option 3.71 3,763 13,961 7,106 03/02/21
Daniel Jennifer EVP & Chief HR Offic.. EVP & Chief HR Officer Mar 02 Sell 105.78 3,763 398,050 6,688 03/02/21
Daniel Jennifer SVP & Chief HR Offic.. SVP & Chief HR Officer Feb 26 Option 3.07 6,689 20,535 10,033 02/26/21
Daniel Jennifer SVP & Chief HR Offic.. SVP & Chief HR Officer Feb 26 Sell 110.55 6,689 739,469 6,688 02/26/21
- - - Feb 24 Sell 109.57 457,693 50,149,422 8,857,890 02/24/21
Daniel Jennifer SVP & Chief HR Offic.. SVP & Chief HR Officer Feb 24 Option 3.07 6,688 20,532 10,032 02/24/21
Daniel Jennifer SVP & Chief HR Offic.. SVP & Chief HR Officer Feb 24 Sell 108.96 6,688 728,724 6,688 02/24/21
Tran Yvonne EVP & Chief Legal Of.. EVP & Chief Legal Officer Feb 23 Sell 113.55 10,000 1,135,500 17,131 02/23/21
D'Cruz Cony EVP & Chief Business.. EVP & Chief Business Officer Feb 22 Option 3.07 2,800 8,596 2,800 02/22/21
D'Cruz Cony EVP & Chief Business.. EVP & Chief Business Officer Feb 22 Sell 102 4,800 489,600 153,082 02/22/21
Lebowitz Joel EVP & CFO EVP & CFO Feb 17 Option 4.34 5,574 24,191 5,574 02/17/21
Lebowitz Joel EVP & CFO EVP & CFO Feb 17 Sell 111.61 5,574 622,114 02/17/21
Lebowitz Joel EVP & CFO EVP & CFO Feb 08 Option 17 12,374 210,358 12,374 02/08/21
Lebowitz Joel EVP & CFO EVP & CFO Feb 08 Buy 99.9 1,115 111,388 02/08/21
D'Cruz Cony EVP & Chief Business.. EVP & Chief Business Officer Feb 04 Option 3.07 2,800 8,596 2,800 02/04/21
D'Cruz Cony EVP & Chief Business.. EVP & Chief Business Officer Feb 04 Sell 94.84 4,800 455,232 157,082 02/04/21
Daniel Jennifer SVP & Chief HR Offic.. SVP & Chief HR Officer Feb 02 Option 4.34 418 1,814 7,106 02/02/21
Daniel Jennifer SVP & Chief HR Offic.. SVP & Chief HR Officer Feb 02 Sell 91.2 418 38,122 6,688 02/02/21
D'Cruz Cony See Remarks See Remarks Jan 15 Option 3.07 2,800 8,596 2,800 01/15/21
D'Cruz Cony See Remarks See Remarks Jan 15 Sell 89.7 4,800 430,560 161,082 01/15/21
- - - Dec 10 Sell 66.84 285,102 19,056,218 9,658,342 12/10/20
- - - Dec 04 Sell 65.29 207,239 13,530,634 9,943,444 12/04/20